Forma Therapeutics Holdings

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. engages in the research, development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the closing of an underwritten public offering of 6,095,000 shares of its common stock.

Forma Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the pricing of an underwritten public offering of 5,300,000 shares of its common stock.

Forma Therapeutics Announces Pricing of Public Offering

WATERTOWN, MA--(BUSINESS WIRE)--Forma Therapeutics launches a proposed public offering of 4,600,000 shares of its common stock.

Forma Therapeutics Launches Proposed Public Offering

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics presents clinical proof-of-concept data on FT-4202 in sickle cell disease at the 62nd ASH annual meeting.

Forma Therapeutics Presents Clinical Proof-of-Concept Data at the 62nd Annual ASH Meeting Supporting the Potential of its Novel Investigational PKR Activator, FT-4202, to Treat Sickle Cell Disease (SCD)

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces financial results for the third quarter ended September 30, 2020.

Forma Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces EU Orphan Drug designation for FT-4202 for the treatment of sickle cell disease.

Forma Therapeutics Announces FT-4202 Receives Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma announced that four abstracts have been accepted for presentation at the 62nd American Society of Hematology (ASH) Virtual Annual Meeting.

Forma Therapeutics Announces Four Oral and Poster Presentations on FT-4202 in Sickle Cell Disease at Upcoming 2020 ASH Virtual Annual Meeting

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces positive top-line data from planned interim analysis of Phase 2 trial evaluating olutasidenib in acute myeloid leukemia.

Forma Therapeutics Announces Positive Top-line Olutasidenib Data From a Planned Interim Analysis of a Registrational Phase 2 Clinical Trial in Acute Myeloid Leukemia (AML)

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the appointments of two new vice presidents

Forma Therapeutics Appoints Two New Vice Presidents to Lead Key Organizational Functions

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the appointment of Thomas G.

Forma Therapeutics Appoints Biopharma Veteran Thomas G. Wiggans to Board of Directors

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics reports financial results for the second quarter ended June 30, 2020 and provides business update.

Forma Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces that Wayne A.I.

Forma Therapeutics Elects Distinguished Researcher and Physician Wayne A.I. Frederick, M.D.

Bio-Rad Laboratories

IMARA

Keros Therapeutics

Vaxcyte

Avidity Biosciences

Repare Therapeutics

SPDR S&P Biotech ETF

Zentalis Pharmaceuticals

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax.

Biotech IPOs are booming -- but it's not all about Covid-19

Investors fed their voracious appetites for biotech Friday when two life science companies traded well above offering prices in their market debuts.

Repare and Forma Shares Gobbled Up in IPO

News for Forma Therapeutics Holdings Stock (FMTX)